AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Stocksdownunder

Published November 5, 2026 · Updated November 6, 2026

Compass Pathways (NDQ: CMPS): Can Psychedelic Therapy Become Mainstream Medicine ...

Read the full story at Stocksdownunder

Healthcare Stocks · Biotech Stocks Precigen (NDQ:PGEN): The First Act Was FDA Approval, The Second Is Competition November 6, 2026. Gaming stocks.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelic biotech